Dynegy Inc. Buyback
OLI recorded this information on 8/6/2015
Company:
Dynegy Inc.
Buyback:
DYN buyback
$Amount Authorized:
$250,000,000
Buyback Details:
In connection with the Company's financial outlook, the continuing reduction in generation supply, and the overall decline of equities in the commodity and power sector, Dynegy's Board of Directors has authorized a share repurchase program accelerating the Company's capital allocation plans. The share repurchase program for up to $250 million is being initiated in the third quarter of 2015 with targeted completion in 2016.
Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue.
DYN SEC Filing Email Alerts Service
Preferred: DYN.PRA
Open the DYN Page at The Online Investor »
|
||||||||||||||||||||||||
Open the DYN Page at The Online Investor (in a new window) »
 Free DYN Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 93rd percentile
(ranked higher than approx. 93% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
